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Summary : Gaucher disease is a lysosomal storage disease characterized by
storage of glucocerebroside due to lysosomal glucocerebrosidase deÐciency.
Increased urinary excretion of sialyloligosaccharides and mannosylglycoaspara-
gines has been described for two patients with the infantile form of the disease,
probably as a consequence of obstruction of lysosomal functioning due to the
glycolipid accumulation in lysosomes. By thin-layer chromatography, we found
increased urinary oligosaccharide excretion in a series of adult non-
neuronopathic patients. Oligosaccharide patterns were comparable between
patients and also with the pattern observed in infantile Gaucher disease. Com-
position was analysed by methanolysis and gas chromatography. Mannose and
N-acetylglucosamine are the main carbohydrates in all oligosaccharide bands.
A statistically signiÐcant correlation was found between oligosaccharide excre-
tion and the severity of the disease expressed as severity score index. Patients
treated with enzyme replacement therapy showed a reduction up to 65% of the
original oligosaccharide excretion after 1 year of treatment, comparable with
the reduction in spleen volume.
Gaucher disease (McKusick 230800) is a lysosomal storage disease due to a deÐ-
ciency of acid glucocerebrosidase. Storage of the sphingolipid glucocerebroside is
primarily in cells of the mononuclear phagocytic system. In the chronic, non-
neuronopathic form of the disease (type 1) the main clinical symptoms are hyper-
splenism with haematological abnormalities (thrombocytopenia, anaemia,
leukopenia), hepatomegaly and bone lesions. In the acute (type 2) and subacute
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(type 3) neuronopathic forms the nervous system is also involved (Beutler and Gra-
bowski 1995). Enzyme replacement therapy with modiÐed placental glucocerebrosi-
dase is now applied for the non-neuronopathic form (Barton et al 1991 ; Beutler et al
1991 ; Fallet et al 1992 ; Pastores et al 1993 ; Hollak et al 1995). Urinary oligosac-
charide excretion is increased in lysosomal diseases with deÐciencies of enzymes
involved in the degradation of oligosaccharide originating from glycoproteins
(Thomas and Beaudet 1995). With respect to the sphingolipidoses, oligosaccharide
excretion as a direct consequence of the enzyme deÐciency is seen in GM1-
gangliosidosis and Sandho† disease (Gravel et al 1995 ; Suzuki et al 1995). Increased
excretion of oligosaccharide in Gaucher disease has been described in two patients
with the infantile neuronopathic form probably as a consequence of obstruction of
lysosomal functioning due to the massive glycolipid accumulation in the lysosomes
(Michalski et al 1983). In this paper we describe increased excretion of oligosac-
charide in adult non-neuronopathic patients. The amount of excreted oligosac-
charides appears to be related to the severity of the disease.
METHODS
T hin-layer chromatography of oligosaccharides : Urine specimens (1 ml) were desalted
and freed from monosaccharides by gelÐltration on 15 ml columns containing
Bio-Gel P-2 (Bio-Rad Laboratories, CA, USA). Columns were eluted with deionized
water. When fractions of 1 ml were collected, oligosaccharides were detected in frac-
tions 6È12 and monosaccharides, sodium and creatinine in fractions 13È15. The
oligosaccharide-containing fractions 6È12 were combined, evaporated to dryness in
a Savant AS290 Automatic Speed-Vac concentrator (Savant Instruments, Inc.
Farmingdale NY, USA) and dissolved again in the original volume of 1 ml. Oligo-
saccharides were analysed by thin-layer chromatography on silicagel 60 plates
(Merck, Darmstadt, Germany, no. 5553) (Blom et al 1983). The amount applied (in
kl/cm) depended on the creatinine content of the original urine and was calculated
by the formula 200/creatinine content (in mmol/L). Thin-layer plates were developed
in n-butanolÈacetic acidÈwater (2 : 1 : 1, by vol). A characteristic pattern of eight
oligosaccharide bands below the sialyllactose oligosaccharide referent was seen in
urines from Gaucher patients. Oligosaccharides, sialyloligosaccharides and glyco-
peptides were visualized by orcinol, resorcinol and ninhydrin staining, respectively.
For the orcinol staining, plates were sprayed with a solution of 0.2% orcinol (BDH
Laboratory Supplies, Poole, UK, no. 29418) in 10% sulphuric acid and heated for
20 min at 90¡C. The ninhydrin staining was performed as described (Schindler et al
1990) using ninhydrin from Merck (no. 6762). Resorcinol staining was with a 0.2%
resorcinol (Merck no. 7593) solution in 30% hydrochloric acid. After spraying, the
TLC plate was heated between glass plates for 30È45 min at 100¡C.
OligosaccharidequantiÐcation : Aquantitativemeasureof theoligosaccharide content
was obtained by measurement of mannose content of the oligosaccharide fraction
(obtained after the Bio-Gel P-2 chromatography) quantiÐed by gas chromatography
after methanolysis as described by Chaplin (1986) with some modiÐcations. Volumes
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of 50 and 100 kl desalted urines to which 25 nmol of an internal standard
(myoinositol) was added were dried by evaporation of the water and by placement
in a vacuum desiccator over Methanolysis was performed by incubation withP2O5 .
200 kl water-free methanolic HCl (0.5 mol/L) (Supelco, Bellefonte, PA, USA, no.
3-3095) during 24 h at 80¡C. After neutralization to pH 5È6 (pH test strip) with
hexosamines were reacetylated by the addition of 50 kl acetic anhydrideAg2CO3 ,
and an overnight incubation at room temperature. Supernatants obtained after cen-
trifugation were dried by evaporation. Derivatization was by incubation with 60 kl
N,O-bis(trimethylsilyl)triÑuoroacetamide (BSTFA) (Pierce Europe B.V., Oud Beijer-
land, The Netherlands, no. 38832) in pyridine (1 : 1, v/v) solution at 60¡C during 2 h.
The trimethylsilylated methylglycosides obtained were quantiÐed by gas chromatog-
raphy with myoinositol as an internal standard on a HP 5880 gas chromatograph
using an Ultra 1 HP column with a length of 25 m, a diameter of 0.2 mm and a Ðlm
thickness of 0.11 km, both from Hewlett Packard Nederland BV, Amstelveen, The
Netherlands. The temperature program was started at 120¡C (5 min) followed by a
temperature gradient from 120¡C to 220¡C. The column was regenerated at 295¡C
(5 min). Split ratio was 1 : 20, injector temperature was 250¡C, and the detector
temperature was 300¡C. Injection volume was 2 kl.
Analysis of oligosaccharide bands : To analyse the composition of the eight oligo-
saccharide bands, seen on TLC below the sialyllactose reference compound, the
corresponding oligosaccharides were isolated from 2.50 ml urine (creatinine value
6.55 mmol/L) from a Gaucher patient. The urine was desalted with a 125 mg
Duolite mixed bed resin ion exchanger (BDH Ltd, no, MB 5113) essentially as
described by de Jong and colleagues (1994). The desalted urine was concentrated to
500 kl and applied to two 20] 20 cm TLC plates on two strokes of 15 cm each.
The thin-layer plate was partially stained by spraying with orcinolÈsulphuric acid
solution (0.5 cm at each side of the lanes). Unstained areas corresponding to the
eight oligosaccharide bands and the origin were scraped o† and oligosaccharides
were eluted with water. Part of the nine eluted fractions (36%) was used for rechro-
matography on TLC. Fractions gave one band by orcinol staining. They were also
tested with resorcinol (sialyloligosaccharides, sialylglycopeptides) and ninhydrin
(glycopeptides) staining. The other part (64%) was used for analysis of the sugar
composition and was therefore methanolysed with methanolic HCl, reacetylated,
derivatized with BSTFA, and analysed by gas chromatography as described.
Patients and controls : Twenty-six adult type 1 Gaucher disease patients and one
type 2 patient were studied. For all Gaucher type 1 patients a severity score index
was established according to the criteria described by Zimran and colleagues (1992).
Increases in spleen and liver volumes were calculated by subtracting normal values
for liver and spleen (2.5% and 0.2% of body weight, respectively) from measured
organ values. Liver and spleen volumes were measured by spiral computed axial
tomography as described (Hollak et al 1995).
Enzyme treatment : Adult type 1 Gaucher patients were treated with modiÐed glu-
cocerebrosidase (Ceredase, alglucerase, Genzyme, MA, USA; 1.15 U/kg 3 times a
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week) as described by Hollak and colleagues (1995). Oligosaccharide excretion, liver
volume and spleen volume were measured before therapy and after a period of 6
and 12 months.
Chitotriosidase : Chitotriosidase activity in plasma was measured as described by
Hollak and colleagues (1994).
Statistical analysis : (Pearson) Correlation coefficients were calculated and tested
for their signiÐcance by standard procedures. For the calculations, the logarithm of
the measured mannose excretion was always used (Keene 1995). All calculations
were performed by means of Statistical Analysis System (SAS) procedures.
RESULTS
T hin-layer chromatography: In TLC patterns from non-neuronopathic patients at
least eight orcinol-positive bands were visible in the area below the sialyllactose
referent in positions where in the normal control patterns no bands or only weak
bands were detectable (Figure 1a and 1b). From these eight bands at least four were
recognized as resorcinol (sialic acid)-positive (bands 3, 5, 6 and 8), both in TLC
patterns directly obtained from urines and in those obtained after rechromatog-
raphy of the bands isolated by preparative TLC (see Methods). TLC patterns
obtained after rechromatography of isolated bands showed clear ninhydrin positiv-
ity for most of the corresponding bands, including the origin. For bands 4 and 5,
although positive with ninhydrin staining, the intensity was weak, as it was also for
the orcinol staining. Although the rechromatographed isolated bands gave single
bands after orcinol staining they do not necessarily correspond to one oligosac-
charide, as only a one-step puriÐcation procedure was followed. Urinary TLC pat-
terns from the various patients were comparable, but there was a variation in
intensity of the total pattern between patients. The eight orcinol-positive bands were
also visible in the pattern obtained from the urine of an infantile neuronopathic
patient.
Carbohydrate composition of T L C bands : For this purpose the oligosaccharides
corresponding to the eight bands were isolated from urine samples from 26 adult
type 1 Gaucher patients by preparative TLC as described under Methods. The car-
bohydrate composition of each band revealed a high mannose, N-acetylglucosamine
and galactose content, while N-acetylgalactosamine was almost absent (Table 1).
Carbohydrates in these bands therefore apparently derive mainly from N-linked
oligosaccharides.
Oligosaccharide excretion and severity of disease : Mannose content (measured by
gas chromatography and expressed per mmol creatinine) was considered to be a
quantitative measure for the amount of excreted oligosaccharides obtained after gel
Ðltration. Zimran and colleagues (1992) devised a severity score index (SSI) for the
objective determination of the phenotypic expression of the disease. The criteria for
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Figure 1 Thin-layer chromatography of urinary oligosaccharides. (a) Urines were desalted
with Duolite mixed bed resin ion exchanger (de Jong et al 1994). HD, partially hydrolysed
dextran, containing glucose monomer, dimer, trimer, etc., used as reference compound. G,
urines from adult Gaucher patients. C, urines from two di†erent non-Gaucher individuals. (b)
Oligosaccharides were partially puriÐed by gel Ðltration on a Bio-Gel P2 column and chro-
matographed as described under Methods. HD, partially hydrolysed dextran, containing
glucose monomer, dimer, trimer, etc., used as reference compound. G1, infantile neurono-
pathic Gaucher patient. G2.1 and G2.2, adult Gaucher patient, before (G2.1) and during
(G2.2) enzyme replacement therapy. G3, adult Gaucher patient. S, urine from a sialidosis
patient. R, reference compounds : glucose, lactose and sialyllactose (from top to bottom)
scoring are primarily based on the extent of organ involvement and degree of cyto-
penia. A positive statistically signiÐcant correlation was found between
oligosaccharide-bound mannose (expressed as ln[mannose]) and the severity score
index (Figure 2, Table 2). We also calculated the correlation with the independent
parameters on which the SSI is based and found a positive statistically signiÐcant
correlation with increase in spleen volume and a statistically signiÐcant negative
correlation with haemoglobin content (Table 2).







Table 1 Carbohydrate composition of oligosaccharide bands
Neuraminicb
No. Orcinola Resorcinola Ninhydrina Mannoseb GlcNAcb,c Galactoseb acid Fucoseb GalNAcb,c
1 ] [ ] 56 26 12 È 1 4
2 2] [ 2] 50 21 22 2 3 3
3 2] ] 2] 33 21 32 6 5 3
4 ] [ ^ 46 35 10 2.5 3 3
5 ] ^ ] 46 32 13 6 3 È
6 2] ] ^ 44 34 14 6.5 2 È
7 ^ ? ] 46 31 14 5 4 È
8 ] ] ] 38 30 18 10 4 È
Origin 2] ] 2] 18 33 23 15 6 5
a 2], clearly positive ;] , positive ; ^, weakly positive ; ?, dubiously positive
b Percentage (mol) of total per band
c GlucNAc, N-acetylglucosamine ; GalNAc, N-acetylgalactosamine
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Figure 2 Correlation between severity score index and excretion of oligosaccharide-bound
mannose. Lines represent the 95% interval of conÐdence for individual observations
InÑuence of enzyme therapy on oligosaccharide excretion : Table 3 gives the relative
reduction in oligosaccharide excretion before and after 6È7 and 12È14 months of
enzyme replacement therapy for 3 adult type 1 non-splenectomized Gaucher
patients together with the reduction in their spleen and liver volumes. As a second
biochemical parameter, the relative reduction in chitotriosidase activity is given.




SSI 26 0.61 0.001
Increase in spleen volume 11 0.79 0.004
Increase in liver volume 23 0.27 0.20
Haemoglobin 19 [0.47 0.04
Thrombocytes 19 [0.20 0.4
ln[mannose]\ logarithm of mannose excretion
(oligosaccharide-bound)
n \ number of patients ; r \ Pearson coefficient of correlation ;
p \ p-value, signiÐcance level
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Table 3 Changes in mannose excretion, spleen volume, liver volume and chitotriosidase activ-
ity during alglucerase therapy
Period of Mannose Spleen L iver Chitotriosidase
treatment excretion volume volume activity
Patient (months) (%) (%) (%) (%)
1 0È7È12 100È100È83 100È75È66 100È89È76 100È91È83
2 0È6È12 100È67È67 100È65È66 100È97È100 100È58È51
3 0È6È14 100È56È65 100È72È59 100È92È82 100È85È44
DISCUSSION
The main storage product in Gaucher disease is glucosylceramide, due directly to
the glucocerebrosidase deÐciency. This glycolipid is mainly derived from membranes
of phagocytosed leukocytes and senescent erythrocytes (DeGasperi et al 1990). Gly-
coprotein storage in spleen and liver from type 1 and type 3 Gaucher patients has
been described by DeGasperi and colleagues (1990). Urinary excretion of sialyloligo-
saccharides and high-mannose-type glycoasparagines in two infantile Gaucher
patients has been described by Michalski and colleagues (1983). In this investigation
we detected urinary excretion of oligosaccharides and glycopeptides in adult non-
neuronopathic (type 1) patients. Thin-layer chromatography patterns from the
various patients were comparable with each other but showed some variation
between patients in intensity of the orcinol-stained bands. Mannose and N-
acetylglucosamine were the main sugar residues. Most of the orcinol-positive bands
were also ninhydrin-positive and some of them resorcinol-positive. They therefore
apparently correspond to N-glycosidic type glycopeptides and oligosaccharides
derived from N-glycosidically linked oligosaccharides. Michalski and colleagues
(1983) puriÐed and analysed sialyloligosaccharides and several glycopeptides from
infantile Gaucher urine. The oligosaccharides appeared to be comparable with the
N-acetyllactosamine (complex) type oligosaccharides seen in sialidosis urines. The
glycopeptides in their study contained only mannose and N-acetylglucosamine
sugar residues and were identiÐed as glycoasparagines related to high-mannose-type
carbohydrate chains of glycoproteins. Ninhydrin-positive bands analysed in our
study, however, also contained galactose and some also neuraminic acid (bands 3, 5,
6 and 8). Bands isolated from the thin-layer chromatogram in our investigation
probably do not correspond to homogeneous oligosaccharide or glycopeptide prep-
arations. The galactose and neuraminic acid in ninhydrin-positive bands may be
due to a combination of the glycopeptides and sialyloligosaccharides described by
Michalski and colleagues (1983). There were no similarities seen between the pat-
terns obtained from Gaucher urines and that from a sialidosis urine (Figure 1b).
Storage of glycoprotein material in spleen and liver (DeGasperi et al 1990) is
apparently a secondary phenomenon due to obstruction of lysosomal enzymes,
caused by the massive storage of glucosylceramide (Michalski et al 1983). DeGasperi
and colleagues (1990) detected intense staining of Gaucher cells in liver and spleen
with lectins that react with N-linked mannose- and fucose-containing oligosac-
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charide, with N-acetyllactosamine sequences therein and with terminal galactose
and neuraminic acid residues. This kind of partially degraded material might reach
the circulation and will then be secreted in the form of glycopeptides.
The clinical presentation for type 1 Gaucher disease is variable and no relation
can be made with biochemical parameters such as enzyme activity (van Weely et al
1991). A correlation has been demonstrated between di†erent genotypes and the
expression in Gaucher phenotypes 1 to 3 (Theophilus et al 1989 ; Zimran et al 1989 ;
Beutler 1991 ; Sibille et al 1993). With respect to type 1 disease, symptomatic
patients with genotypes other than N370S homozygosity generally have more severe
disease than do N370S homozygotes (Sibille et al 1993 ; NIH Technology Assess-
ment Panel on Gaucher Disease 1996). On the other hand, variation in clinical
expression is seen within the same mutation group (Sidransky et al 1992 ; Zimran et
al 1992 ; NIH Technology Assessment Panel on Gaucher Disease 1996), which may
be due to secondary factors such as variations in activator activities, the inÑow of
glycolipid into the lysosomal system, or viral infection (Zimran et al 1992). There is
a need for more biochemical parameters in Gaucher disease to allow character-
ization and prediction of progression of disease or the e†ect of therapy (Aerts et al
1993). We found a signiÐcantly positive correlation between oligosaccharide excre-
tion and clinical severity of the disease expressed as severity score index (Table 2).
Excretion of oligosaccharides was also signiÐcantly positively correlated with spleen
size. If the excretion is caused by a secondary accumulation of glycoproteins and
glycopeptides due to obstruction of the lysosomal system by an excessive amount of
glycolipids, there may be a relation between oligosaccharide excretion and the
amount of glycolipid stored in the body. Storage in Gaucher disease is most promi-
nent in cells of the mononuclear phagocytic system like the spleen. Another source
for the urinary glycopeptides could be the kidney. If oligosaccharide excretion
indeed is a measure for the extent of storage, it would be an interesting parameter
for long-term follow-up of therapy.
Table 3 shows the inÑuence of enzyme therapy on reduction of oligosaccharide
excretion, reduction of spleen and liver volume and reduction in plasma chitotriosi-
dase activity after 6È7 and 12È14 months of therapy. Mannose excretion, spleen
volume and chitotriosidase activity decreased to a similar extent. The e†ect of
therapy on these biochemical parameters, and correlation with clinical improvement
and other parameters such as regression of spleen and liver volume, haemoglobin
content and platelet count will be the subjects of further investigation.
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